Objectives: The aims of this investigation were to compare prevalence and severity of lower urinary tract symptoms (LUTS) in both sexes and to analyze their effect on everyday life (‘botherness’) in a cross–sectional study design. Methods: Individuals participating in a health survey in Vienna completed a German version of the Bristol LUTS questionnaire. In this questionnaire, storage (irritative) and voiding (obstructive) symptoms were assessed by six items, each followed by a quality of life (‘botherness’) question. Results: A consecutive series of 1,191 women (49.8±13.5 years) and 1,211 men (48.5±11.9 years) were analyzed. The mean increase in LUTS from the youngest (20–39 years) to the oldest (>70 years) age group was 43.7% (7.3%/decade) for men and 23.6% (3.9%/decade) for women. In all decades, storage symptoms were higher for women. Beyound the age of 60 years this discrepancy declined. Voiding symptoms were almost identical in both sexes until the 5th decade, thereafter they increased significantly in men but not in women. ‘Urgency’ and ‘frequency’ were more bothersome to older individuals, ‘nocturia’ and voiding symptoms were almost equally bothersome to younger and older participants. Conclusions: These data provide insights into the development of storage and voiding problems with age in both sexes. Sex– and age–stratified analyses of quality of life impairments (‘botherness’) due to LUTS have demonstrated the importance of age for the impact of LUTS on the bother score.

Keywords:
Micturition disorder, Prevalence, Men, Women, Bladder, Urodynamics
1.
Fultz NH, Herzog A: Epidemiology of urinary symptoms in the geriatric population. Urol Clin North Am 1996;23:1–10.
2.
Elbadawi A, Diokno AC, Millard RJ: The aging bladder: Morphology and urodynamics. World J Urol 1998;16(suppl 1):S10–S34.
3.
Abrams P: New words for old: Lower urinary tract symptoms for ‘prostatism’. BMJ 1994; 308:929–930.
4.
Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holgrewe HL, Mebust WK, Cockett ATK and Measurement Committee of the American Urological Association: The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148: 1549–1557.
5.
Cockett ATK, Aso Y, Denis L, Murphy G, Khoury S, Abrams P, Barry M, Carlton GE, Fitzpatrick J, Gibbons R, Griffiths K, Hald T, Holtgrewe L, Jardin A, McConnell J, Mebust W, Roehrborn C, Smith P, Stepg A, Walsh P: Recommendations of the International Consensus Committee concerning Prostate Symptom Score (I–PSS) and Quality of Life Assessment; in Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, Murphy G (eds): The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey, Scientific Communication International, 1994, pp 53–55.
6.
Garraway WM, Collins GN, Lee RJ: High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469–471.
7.
Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, Lieber MM: The prevalence of prostatism: A population–based survey of urinary symptoms. J Urol 1993;150: 85–89.
8.
Sagnier PP, MacFarlane G, Richard F, Botto H, Teillac P, Boyle P: Results of an epidemiological survey using a modified American Urological Association symptom index for benign prostatic hyperplasia in France. J Urol 1994; 151:1266–1270.
9.
Madersbacher S, Haidinger G, Temml C, Schmidbauer CP for the Prostate Study Group of the Austrian Society of Urology: The prevalence of lower urinary tract symptoms in Austria as assessed by an open survey of 2096 men. Eur Urol 1998;34:136–141.
10.
Chai TC, Belville WD, McGuire EJ, Nyquist L: Specificity of the American Urological Association voiding symptom index: Comparison of unselected and selected samples of both sexes. J Urol 1993;150:1710–1713.
11.
Lepor H, Machi G: Comparison of AUA symptom index in unselected males and females between fifty–five and seventy–nine years of age. Urology 1993;42:36–41.
12.
Diokno AC, Brock BM, Brown MB, Herzog R: Prevalence of urinary incontinence and other urological symptoms in the noninstitutionalized elderly. J Urol 1986;136:1022–1025.
13.
Pinnock C, Marshall VR: Troublesome lower urinary tract symptoms in the community: A prevalence study. Med J Aust 1997;167:72–75.
14.
Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs R, Fourcade R, Kiemeney L, Lee C: A comparison of lower urinary tract symptoms (LUTS) in men and women in four centers: The UREPIK study. J Urol 2000;163(suppl): 48.
15.
Temml C, Haidinger G, Schmidbauer J, Schatzl G, Madersbacher S: Urinary incontinence in both sexes – Prevalence rates, impact on quality of life and sexual life. Neurourol Urodyn 2000;19:259–271.
16.
Jackson S, Donovan J, Brookes S, Eckford S, Swithinbank L, Abrams P: The Bristol female lower urinary tract symptoms questionnaire: Development and psychometric testing. Br J Urol 1996;77:805–812.
17.
Schatzl G, Temml C, Schmidbauer J, Dolezal B, Haidinger G, Madersbacher S: A cross–sectional study of nocturia in both sexes: Prevalence rates, impact on quality of life and factors related to severity. Urology 2000;56:71– 75.
18.
Haidinger G, Madersbacher S, Waldhoer T, Lunglmayr G, Vutuc C: The prevalence of lower urinary tract symptoms in Austrian males and associations with sociodemographic parameters. Eur J Epidemiol 1999;15:717– 722.
19.
Swithinbank LV, Abrams P: A detailed description, by age, of lower urinary tract symptoms in a group of community–dwelling women. Br J Urol Int 2000;85(suppl 2):19–24.
20.
Madersbacher S, Pycha A, Schatzl G, Mian C, Klingler HC, Marberger M: The aging lower urinary tract: A comparative urodynamic study of men and women. Urology 1998;51: 206–212.
21.
Van Mastrigt R: Age dependence of urinary bladder contractility. Neurourol Urodyn 1992; 11:315–317.
22.
Mark SD, Gilling PJ, van Mastrigt R, Arnold EP, McRae CU: Detrusor contractility: Age related correlation with urinary flow rate in asymptomatic males. Neurourol Urodyn 1992; 11:315–317.
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.